MDS

Key inclusion criteria:
- Participants with histological confirmation of advanced hematologic malignancy including:
a. R/R AML, as defined by standardized criteria (e.g., European LeukemiaNet criteria [Dohner 2022]; after standard of care therapy. Participants with persistent leukemia after initial therapy or with recurrence of leukemia at any time after achieving a response during or after the course of treatment (including HSCT) are eligible.
b. R/R HR-MDS or very high risk MDS as per the Revised International Prognostic Scoring System (IPSS-R; Greenberg 2012) or Molecular International Prognostic Scoring System (IPPS-M, Bernard 2022) who are resistant or refractory to 4-6 cycles of hypomethylating agents (HMA; decitabine or azacitidine).
c. R/R CMML who are resistant or refractory to 4-6 cycles of hypomethylating agents (HMA; decitabine or azacitidine)

- White blood cells must be below 25,000/µL at time of enrollment. Participants may receive cytoreduction prior to enrollment.

- Historical documented evidence of HLA-A*02:01 allele positivity

-ECOG 0-1

Key exclusion criteria:
- Previous CTSG targeted therapy or treatment with any pMHC T-cell engager

- Isolated extramedullary relapse.

- Active central nervous system (CNS) disease.